Exicure, Inc. to Present at Ladenburg Thalmann 2021 Healthcare Conference
June 29 2021 - 7:00AM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced that CEO David Giljohann will present a
company update as well as participate in a series of 1x1 meetings
at the Ladenburg Thalmann 2021 Healthcare Conference occurring July
13-14, 2021.
Presentation Date: July 13, 2021 Presentation
Time: 1:00-1:25 PM in Track One Location: The panel
discussion will be webcast (available here)
Replays of the presentation will be available on Exicure’s
website for 30 days following the presentation.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on its
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210629005162/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024